Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Socie...
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica's novel oncolytic peptide for the treatment of basal cell carcinoma. The data will be presented at the upcoming 2026 Society for Investigative Dermatology (SID) Annual Meeting, which will take place from May 13-16, 2026, in Chicago, Illinois. Presentation Details: Title: “VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors” Poster Number: LB1190 Category: Non-Melanoma Cancers and UV Biology/Injury Poster Session Dates and Time: Friday, May 15, 2026 (4:30 pm – 6:00 pm) Location: (Salons B,C,D - Lower Level, Hilton Chicago) About VP- 315 (ruxotemitide) VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induc
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingGlobeNewswire
- Verrica Pharmaceuticals (VRCA) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmBusiness Wire
VRCA
Earnings
- 3/11/26 - Miss
VRCA
Sec Filings
- 3/11/26 - Form 10-K
- 3/11/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- VRCA's page on the SEC website